Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(1):86-87; doi:10.1093/jnci/djk012
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tam-McDevitt, J. T.
Right arrow Articles by Lichtman, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tam-McDevitt, J. T.
Right arrow Articles by Lichtman, S. M.
Related Collections
Right arrowCorrespondence about this Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Has Demand for Clinical Trial Participants Outpaced Supply?

Jennifer T. Tam-McDevitt, Lodovico Balducci, Robert S. Hauser, Daniel Gura, Aram Paraghamian, Heidi Thomas, Stuart M. Lichtman

Affiliations of authors: Geriatric Oncology Consortium, Baltimore, MD (JTTM, RSH, DG, AP, HT); Senior Adult Oncology, H. Lee Moffitt Cancer Center, Tampa, FL (LB); Department of Medicine, Memorial Sloan-Kettering Cancer Center, Commack, NY (SML)

Correspondence to: Jennifer T. Tam-McDevitt, PharmD, PhD, Geriatric Oncology Consortium, 3600 Clipper Mill Rd., Ste. 110, Baltimore, MD 21211 (e-mail: jtam@thegoc.org).

The first 10% of the full text of this article appears below.

Clinical trials are a critical resource for the discovery of new preventive, diagnostic, and treatment methods for cancer. However, current estimates show that less than 10% of adult cancer patients in the United States participate in clinical trials (1). Low trial participation combined with the requirements of larger patient populations per trial and more trials in each study phase for drug approval (2) may . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Correspondence about this Article

Re: Has Demand for Clinical Trial Participants Outpaced Supply?
Ronald S. Go, Lori A. Meyer, and Kathleen A. Frisby
J Natl Cancer Inst 2007 99: 973. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. S. Go, L. A. Meyer, and K. A. Frisby
Re: Has Demand for Clinical Trial Participants Outpaced Supply?
J Natl Cancer Inst, June 20, 2007; 99(12): 973 - 973.
[Full Text] [PDF]